Home / Case Studies / Nootropic Brand CBG Co-Formulation

Nootropic Brand CBG Co-Formulation

An established nootropic supplement brand added a CBG-forward gummy to their existing line using a custom 1:2 CBD:CBG ratio — co-formulated and private-labeled through Steve's Goods. First reorder at six months.

What They Ordered and Why

This buyer had been selling nootropic supplements for four years and knew their customer well: a daily supplement user, 28–44 years old, who reads ingredient labels and makes deliberate formulation choices. Their customer was already asking about cannabinoids — specifically CBG, which had come up in nootropic communities online. The buyer had been waiting for the right formulation partner before adding hemp to their line.

They chose a custom 1:2 CBD:CBG ratio rather than a stock formulation because they wanted CBG to be clearly the lead compound — not just an addition to a CBD product. The 12.5mg CBD + 25mg CBG ratio was designed to read "CBG product with a CBD note" rather than "CBD product with some CBG." That distinction mattered for how they wanted to position it in their existing product lineup: this was the CBG product, not the CBD product.

The private-label route rather than white-label was chosen because the stock 1:1 and 2:1 formulations did not match their target ratio — and because custom formulation gave them a formulation they could call proprietary within their brand positioning.

The R&D Process

The formulation brief was signed in week 1. The buyer's input: 25mg CBG per gummy as the anchor, a citrus-forward flavor profile (to match their existing L-theanine product's packaging language), a 30-count pouch, and a clean ingredient declaration with no artificial sweeteners.

First R&D batch in week 3: a strawberry-citrus flavor that came back slightly sweet-forward. Second R&D batch in week 5: adjusted flavor balance with a lemon-forward natural citrus flavor. Buyer approved the second R&D batch. COA returned in week 7: CBG confirmed at 25.1mg per gummy, CBD at 12.4mg, total THC at 0.19mg per container. Full safety panel clean.

Production at 3,000 units ran in weeks 8 through 9. Ship in week 10, exactly on the projected timeline.

What Worked

The two things that made this project run cleanly: the buyer submitted print-ready artwork before production started (not during), and they had a clear formulation brief from the first call. Both of those factors eliminated the most common delays in custom-formulation projects — artwork revisions that delay label approval, and formulation changes mid-development that restart the R&D batch sequence.

From a sales standpoint, the CBG gummy launched as a "focus stack companion" to their existing lion's mane product on their DTC site. The pairing — lion's mane capsules + CBG gummy as a morning stack — gave their email list a specific routine suggestion without making efficacy claims about either product. The bundle sold through the first 3,000-unit run in approximately five months.

On the reorder, the buyer added a 10mg CBG-isolate SKU as a second, lower-entry-price product for customers who were curious about CBG but hesitant to start at 25mg. The two-SKU CBG set — a 10mg entry and a 25mg premium — mirrors the same tiered approach that works well in retail accounts. By bundling 4,000 units of the 1:2 blend with 1,000 units of the CBG-isolate 10mg, they reached 5,000 total units and qualified for the 5,000–9,999 tier pricing.

What to Take From This Account

Custom formulation is the right path when a standard ratio does not match your brand's positioning intent — and when you have the timeline flexibility (10 weeks minimum) to develop and test it properly. For brands with an existing nootropic or supplement identity, a CBG-dominant formulation positions naturally as the hemp addition to an existing stack rather than a hemp-category SKU trying to be a supplement.

The practical advice: submit your formulation brief early, get your artwork ready before production, and plan for two R&D batches in your timeline budget. One R&D batch is optimistic; three is uncommon but possible on complex flavor development. Two is the honest planning number for a custom flavor target.

See CBD+CBG Blends — Which Ratio to Stock for the full breakdown of ratio options, and the white-label page for the R&D timeline detail and what goes into a batch COA.

Representative buyer profile — anonymized for confidentiality. Operational details are typical for accounts at this volume tier. These statements have not been evaluated by the FDA. Our products are not intended to diagnose, treat, cure, or prevent any disease.